ÂÜÀòÂÒÂ×

Jordi Xiol is a seasoned professional in the fields of investment and biomedical research, currently serving as a Partner at Ysios Capital since May 2019, with previous roles including Principal, Senior Associate, and Associate at the same firm. Jordi Xiol actively participates on several boards, including roles as Board Member for Northsea Therapeutics and Board Observer for SpliceBio, CytoKi Pharma, and Adcendo. Prior experience includes serving as a Venture Fellow at Vida Ventures, LLC, focusing on clinical and scientific due diligence in gene therapy, oncology, and ophthalmology. Academic credentials include a Ph.D. in Cell and Molecular Biology from the European Molecular Biology Laboratory and University of Grenoble, and a B.Sc. in Biochemistry from Universitat de Barcelona. Jordi Xiol's postdoctoral research at Harvard University under Dr. Fernando Camargo explored signaling pathways in intestinal epithelium regeneration and cancer stem cell dynamics.